TRESIBA 200 UNIT
INSULIN DEGLUDEC : 200 UNIT · DIN 02467887 · NOVO NORDISK CANADA INC
Health Canada status: MARKETED
What is TRESIBA?
TRESIBA 200 UNIT contains INSULIN DEGLUDEC : 200 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02467887, held by NOVO NORDISK CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 15-Sep-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TRESIBA used for?
TRESIBA® is indicated for once-daily treatment of adults with diabetes mellitus to improve glycemic control. It is also indicated for the treatment of pediatric patients (≥ 2 years old) with Type 1 diabetes mellitus.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02467887 |
|---|---|
| Brand name | TRESIBA |
| Generic / active ingredient | INSULIN DEGLUDEC : 200 UNIT |
| Manufacturer | NOVO NORDISK CANADA INC |
| Strength | 200 UNIT |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Schedule D |
| ATC code | A10AE06 INSULIN DEGLUDEC |
| AHFS class | 68:20.08.16 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 15-Sep-2017 |
| Original market date | 2017-09-15 00:00:00 |
How is it stored and handled?
null
How is it supplied?
1 x 3 mL, 5 x 3 mL (U-100 FlexTouch®); 1 x 3 mL, 3 x 3mL (U-200 FlexTouch®); 5 x 3 mL (U-100 Penfill®)
What can be used instead?
Other Canadian products sharing ATC code A10AE06 INSULIN DEGLUDEC. 3 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| TRESIBA | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | DIN 02467860 |
| TRESIBA | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | DIN 02467879 |
Who else supplies INSULIN DEGLUDEC worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. INSULIN DEGLUDEC appears in 441 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.